AbbVie's Rinvoq Succeeds Against The Odds In Phase II Lupus Trial
Advances To Pivotal Program
Executive Summary
Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.